EndoQuest Robotics, a Houston, TX-based medical device company, raised $42M in C-1 funding.

位于德克萨斯州休斯顿的医疗器械公司EndoQuest Robotics在C-1资金中筹集了4200万美元。

The round was led by CE Ventures and McNair Interests, along with Puma Venture Capital LLC as a new investor.

该轮由CE Ventures和McNair Interests以及Puma Venture Capital LLC作为新投资者领导。

The newly acquired capital will be instrumental in driving key initiatives, including further research and development, regulatory milestones, commercialization efforts, and strengthening the Company’s position as the frontrunner in flexible endoluminal robotics.

新收购的资金将有助于推动关键举措，包括进一步的研发，监管里程碑，商业化努力，以及加强公司作为灵活腔内机器人领域领先者的地位。

Led by CEO Kurt Azarbarzin, EndoQuest Robotics is a leader in the development of endoluminal robotic technologies. It is focused on addressing the unmet needs in gastrointestinal (“GI”) and other endoluminal surgeries by developing an innovative robotic system that offers precision, flexibility, and improved patient outcomes.

由首席执行官Kurt Azarbarzin领导，EndoQuest Robotics是腔内机器人技术发展的领导者。它的重点是通过开发创新的机器人系统来解决胃肠道（“GI”）和其他腔内手术中未满足的需求，该系统提供精确，灵活和改善患者预后。

The company’s proprietary technology is designed to navigate and perform procedures within the body’s luminal spaces, allowing for minimally invasive interventions and enhancing the capabilities of healthcare professionals..

该公司的专有技术旨在在人体腔内空间内导航和执行程序，从而实现微创干预并增强医疗保健专业人员的能力。。

EndoQuest’s Flexible Robotic System is under development, has not been cleared by the FDA and is not for commercial sale in the United States.

EndoQuest的灵活机器人系统正在开发中，尚未获得FDA的批准，也未在美国进行商业销售 状态。

FinSMEs

FinSME

04/12/2023

04/12/2023